Clinical investigator financial disclosure final rule sets $25,000 payment, $50,000 equity threshold.
This article was originally published in The Gray Sheet
FINANCIAL DISCLOSURE THRESHOLD FOR CLINICAL INVESTIGATORS RAISED TO $25,000 in a final rule published by FDA in the Feb. 2 Federal Register. In its 1994 proposal, the agency had suggested a significantly lower trigger of $5,000 ("The Gray Sheet" Sept. 26, 1994, p. 12).
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.